CryoPort, Inc. (NASDAQ:CYRX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.88.

CYRX has been the topic of several analyst reports. BTIG Research cut their target price on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, July 7th. Morgan Stanley decreased their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. UBS Group raised their target price on shares of CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Roth Mkm reaffirmed a "buy" rating and issued a $15.00 target price on shares of CryoPort in a research report on Tuesday, April 1st. Finally, Guggenheim reaffirmed a "buy" rating and issued a $10.00 target price on shares of CryoPort in a research report on Wednesday, April 16th.

Insider Activity

In other news, Director Robert J. Hariri sold 12,500 shares of the firm's stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $6.10, for a total value of $76,250.00. Following the transaction, the director owned 8,061 shares in the company, valued at approximately $49,172.10. This trade represents a 60.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ramkumar Mandalam sold 13,321 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.01, for a total transaction of $93,380.21. Following the completion of the transaction, the director owned 73,056 shares in the company, valued at $512,122.56. This represents a 15.42% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 449,719 shares of company stock valued at $3,042,327. Corporate insiders own 10.00% of the company's stock.

Institutional Trading of CryoPort

A number of hedge funds have recently modified their holdings of the business. Cadian Capital Management LP raised its position in shares of CryoPort by 14.1% in the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock worth $38,332,000 after purchasing an additional 609,021 shares during the last quarter. Millennium Management LLC raised its position in CryoPort by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock worth $32,208,000 after buying an additional 409,353 shares during the last quarter. Deutsche Bank AG raised its position in CryoPort by 0.9% in the 4th quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock worth $10,870,000 after buying an additional 12,864 shares during the last quarter. Assenagon Asset Management S.A. raised its position in CryoPort by 7.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company's stock worth $8,135,000 after buying an additional 73,949 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in CryoPort by 8.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock worth $6,615,000 after buying an additional 63,301 shares during the last quarter. Institutional investors own 92.90% of the company's stock.

CryoPort Stock Down 3.2%

Shares of CryoPort stock traded down $0.24 on Wednesday, hitting $7.19. 405,537 shares of the company traded hands, compared to its average volume of 476,422. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. CryoPort has a 12-month low of $4.58 and a 12-month high of $9.78. The company has a 50-day moving average price of $6.84 and a 200 day moving average price of $6.65. The company has a market cap of $360.51 million, a PE ratio of -3.07 and a beta of 1.89.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. Sell-side analysts predict that CryoPort will post -0.99 earnings per share for the current year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.